We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Arash Rezazadeh Kalebasty

Arash Rezazadeh Kalebasty MD

Professor, Division of Hematology/Oncology, Department of Medicine, School of Medicine, Chao Family Comprehensive Cancer Center, UCI Health, Orange, CA

Dr. Arash Rezazadeh is a board-certified UCI Health medical oncologist. His clinical interests include immunotherapy and targeted therapies for cancers of the prostate, bladder, kidney and testes.

Rezazadeh earned his medical degree at Shahid Beheshti University of Medical Sciences in Tehran, Iran. He completed a residency in internal medicine and a fellowship in medical oncology and hematology at Kentucky’s University of Louisville School of Medicine.

He has served as principal investigator in numerous clinical trials in the field of genitourinary malignancies, particularly cancers of the bladder and prostate. Some of these trials have led to the approval of novel first-in-class cancer therapies.

Rezazadeh has presented his studies at many national and international cancer conferences, and he has published numerous research papers in his field. He is a member of the American Society of Clinical Oncology, the European Society for Medical Oncology and the NRG Oncology Genitourinary Committee. He is also an editorial reviewer for the publications Bladder Cancer and Annals of Case Reports.